# Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-da-23-017-therapeutic-development-of-psychoplastogenic-compounds-for/  
Official notice: https://www.grants.gov/search-results-detail/341426

> National Institutes of Health offered grants of up to $2.5 million to small businesses. Applications closed on November 18, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-DA-23-017 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | November 18, 2022 |
| Award ceiling | $2.5 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.279 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See Full Announcement for additional details on eligibility

## What the grant funds

This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to develop psychoplastogenic compounds and related models for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.

## Questions people ask

### Is RFA-DA-23-017 still open?

No. It closed on November 18, 2022.

### Who can apply for Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)?

Closed November 18, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $2.5 million each.

### Who has been funded under RFA-DA-23-017?

NIH RePORTER lists 3 projects funded under RFA-DA-23-017 in fiscal 2023, at 3 institutions. The most were at Delix Therapeutics, Bioinvenu Corporation, Consegna Pharma, Inc.

### Who has won Drug Use and Addiction Research Programs grants before?

The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.